Aflibercept (VEGF Trap)

Cat. No.: HY-108801A Purity: 97.66%: FAQs
Data Sheet SDS COA

Molarity Calculator

Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.

For research use only. We do not sell to patients.

Aflibercept (VEGF Trap) Chemical Structure

CAS No. : 862111-32-8

Size	Price	Stock	Quantity
500 μg	USD 530	In-stock	Estimated Time of Arrival: December 31
1 mg	USD 850	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 1950	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Aflibercept (VEGF Trap):

Aflibercept In-stock

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All VEGFR Isoform Specific Products:

View All Isoforms

Biological Activity
Purity & Documentation
References
Customer Review

Description	Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease^[1]^[2]^[3].
CAS No.	862111-32-8
Appearance	Liquid
Color	Colorless to light yellow
SMILES	[Aflibercept (VEGF Trap)]
Shipping	Shipping with dry ice.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Purity: 97.66% Select Batch: Data Sheet (256 KB) SDS (251 KB) COA (231 KB) Handling Instructions (2659 KB)
References	[1]. Klettner A, et al. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis. Br J Ophthalmol. 2014 Oct;98(10):1448-52. [Content Brief] [2]. Kim ID, et al. Aflibercept, a VEGF (Vascular Endothelial Growth Factor)-Trap, Reduces Vascular Permeability and Stroke-Induced Brain Swelling in Obese Mice. Stroke. 2021 Aug;52(8):2637-2648. [Content Brief] [3]. Dong ZC, et al. The vascular endothelial growth factor trap aflibercept induces vascular dysfunction and hypertension via attenuation of eNOS/NO signaling in mice. Acta Pharmacol Sin. 2021 Sep;42(9):1437-1448. [Content Brief]